Effects of Juglone on Neutrophil Degranulation and Myeloperoxidase Activity Related to Equine Laminitis.
electron paramagnetic resonance spectroscopy
juglone
myeloperoxidase
neutrophil degranulation
reactive oxygen species
Journal
Frontiers in veterinary science
ISSN: 2297-1769
Titre abrégé: Front Vet Sci
Pays: Switzerland
ID NLM: 101666658
Informations de publication
Date de publication:
2021
2021
Historique:
received:
08
03
2021
accepted:
08
06
2021
entrez:
2
8
2021
pubmed:
3
8
2021
medline:
3
8
2021
Statut:
epublish
Résumé
Experimental laminitis, characterized by a failure of the dermal-epidermal interface of the foot, can be induced in horses by the oral administration of a black walnut extract (BWE). In the early phase of this severe and painful disease, an activation of neutrophil occurs, with the release of myeloperoxidase (MPO), a pro-oxidant enzyme of neutrophils, in plasma, skin, and laminar tissue. Juglone, a naphthoquinone derivative endowed with redox properties, is found in walnuts and has been incriminated in this neutrophil activation. We report for the first time the inhibitory activity of juglone on the degranulation of neutrophils induced by cytochalasin B and formyl-methionyl-leucyl-phenylalanine as monitored by the MPO release (>90% inhibition for 25 and 50 μM). Moreover, it also acts on the peroxidase activity of MPO by interacting with the intermediate "π cation radical," as evidenced by the classical and specific immunological extraction followed by enzymatic detection (SIEFED) assays. These results are confirmed by a docking study showing the perfect positioning of juglone in the MPO enzyme active site and its interaction with one of the amino acids (Arg-239) of MPO apoprotein. By chemiluminescence and electron paramagnetic resonance techniques, we demonstrated that juglone inhibited reactive oxygen species (ROS) and superoxide anion free radical produced from phorbol myristate acetate (PMA)-activated polymorphonuclear neutrophils (PMNs). These results indicate that juglone is not the trigger for equine laminitis, at least if we focus on the modulation of neutrophil activation.
Identifiants
pubmed: 34336974
doi: 10.3389/fvets.2021.677675
pmc: PMC8322847
doi:
Types de publication
Journal Article
Langues
eng
Pagination
677675Informations de copyright
Copyright © 2021 Mouithys-Mickalad, Storms, Franck, Ceusters, de la Rebière de Pouyade, Deby-Dupont and Serteyn.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Chem Res Toxicol. 2004 Jan;17(1):55-62
pubmed: 14727919
Vet Clin North Am Equine Pract. 2010 Apr;26(1):95-101
pubmed: 20381738
Am J Vet Res. 2007 Jan;68(1):81-6
pubmed: 17199423
Curr Protoc Immunol. 2001 May;Appendix 3:Appendix 3B
pubmed: 18432654
Equine Vet J. 2012 Nov;44(6):752-61
pubmed: 23106629
Vet Hum Toxicol. 2000 Feb;42(1):8-11
pubmed: 10670077
Chem Biol Interact. 2013 Jan 25;201(1-3):49-57
pubmed: 23291280
Chem Biol Interact. 1988;65(2):157-73
pubmed: 2835188
Mol Med Rep. 2015 Sep;12(3):4095-4102
pubmed: 26126609
Met Based Drugs. 1997;4(5):279-85
pubmed: 18475800
Vet Immunol Immunopathol. 2009 Jun 15;129(3-4):158-60
pubmed: 19091425
J Biol Chem. 2006 Jul 14;281(28):19296-304
pubmed: 16675464
Biochim Biophys Acta Gen Subj. 2018 Jul 10;1862(10):2236-2244
pubmed: 30005836
J Appl Toxicol. 1987 Apr;7(2):123-9
pubmed: 3624767
Vet Immunol Immunopathol. 2010 Jun 15;135(3-4):181-7
pubmed: 19939463
J Vet Diagn Invest. 2005 Sep;17(5):412-9
pubmed: 16312231
J Biol Chem. 2009 Sep 18;284(38):25929-37
pubmed: 19608745
Chem Biol Interact. 2013 Nov 25;206(2):194-203
pubmed: 24060682
Eur J Biochem. 2000 Oct;267(19):5858-64
pubmed: 10998045
Vet Immunol Immunopathol. 2006 Oct 15;113(3-4):267-76
pubmed: 16822550
J Am Chem Soc. 2007 May 9;129(18):5846-54
pubmed: 17428049
Am J Vet Res. 1980 Jun;41(6):944-5
pubmed: 7436086
Cell Tissue Res. 2018 Mar;371(3):541-550
pubmed: 29397426
Antioxidants (Basel). 2019 Apr 05;8(4):
pubmed: 30959841
J Agric Food Chem. 2007 Oct 3;55(20):8080-7
pubmed: 17844991
Experientia. 1981 Dec 15;37(12):1233-41
pubmed: 7035210
Vet Immunol Immunopathol. 2011 Dec 15;144(3-4):366-73
pubmed: 21890218
J Immunol. 2012 Nov 1;189(9):4657-65
pubmed: 23002436
J Vet Diagn Invest. 2006 Jul;18(4):326-34
pubmed: 16921870
Toxicology. 2002 Dec 27;181-182:223-7
pubmed: 12505315
Bioinorg Chem Appl. 2016;2016:8636409
pubmed: 27774044
Front Immunol. 2019 Nov 01;10:2567
pubmed: 31736979
Vet Immunol Immunopathol. 2006 Apr 15;110(3-4):195-206
pubmed: 16290066
Vet Immunol Immunopathol. 2016 Mar;171:66-72
pubmed: 26964719
Blood. 1998 Nov 1;92(9):3007-17
pubmed: 9787133
J Biol Chem. 1991 Nov 15;266(32):21496-503
pubmed: 1718980
J Am Vet Med Assoc. 1989 Aug 1;195(3):343-4
pubmed: 2768058
J Biol Chem. 2002 Dec 13;277(50):47976-9
pubmed: 12388558
Res Vet Sci. 1996 Jul;61(1):59-64
pubmed: 8819196
Chemistry. 2018 Apr 3;24(19):4749-4756
pubmed: 29068513
Equine Vet J. 2005 Nov;37(6):546-51
pubmed: 16295933
Mediators Inflamm. 1997;6(5-6):327-33
pubmed: 18472867
Vet Rec. 2010 Oct 30;167(18):690-4
pubmed: 21257484
Nature. 2019 Aug;572(7770):538-542
pubmed: 31367040
Int J Dent. 2013;2013:854765
pubmed: 23878540
Chem Biol Interact. 2019 Jan 5;297:34-43
pubmed: 30342014
Int J Hematol. 2001 Dec;74(4):409-15
pubmed: 11794696
Vet Hum Toxicol. 1987 Jun;29(3):230-3
pubmed: 3604042
Molecules. 2014 Sep 17;19(9):14902-18
pubmed: 25232709
Cell Biol Int. 2009 Oct;33(10):1039-49
pubmed: 19555768
Am J Vet Res. 2005 Mar;66(3):443-9
pubmed: 15822589